-+ 0.00%
-+ 0.00%
-+ 0.00%

Zenas Biopharma prices $200 million 2.50% convertible senior notes due 2032; aggregate gross proceeds rise to $300 million including concurrent stock sale

Reuters·03/27/2026 04:27:30

Please log in to view news